Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Journal: Journal for immunotherapy of cancer
Published: February 28, 2024
Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy.
Journal: Molecular cancer therapeutics
Published: February 06, 2020
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Journal: Cancer chemotherapy and pharmacology
Published: February 01, 2019
Male breast cancer: a disease distinct from female breast cancer.
Journal: Breast cancer research and treatment
Published: July 20, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Journal: Breast cancer research and treatment
Published: April 17, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 16, 2018
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer.
Journal: Hormones & cancer
Published: September 20, 2017
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Journal: European urology
Published: June 26, 2015
Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.
Journal: Therapeutic advances in urology
Published: December 02, 2014
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Journal: European urology
Published: September 22, 2014
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3).
Journal: Investigational new drugs
Published: May 13, 2014
Last Updated: 09/26/2026